Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 898-911

  Kato, Hisayuki ^a,b   Ito, Emma ^a,b   Shi, Wei ^a,b   Alajez, Nehad M ^a,b   Yue, Shijun ^a,b   Lee, Carolina ^a,b   Chan, Norman ^a,b   Bhogal, Nirmal ^a,b   Coackley, Carla L ^a,b   Vines, Doug ^a,b   Green, David ^b   Waldron, John ^a,b   Gullane, Patrick ^b   Bristow, Rob ^a,b   Liu, Fei Fei ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GMX 1777; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE METABOLISM; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOCAL THERAPY; MOUSE; NONHUMAN; PLEIOTROPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR CELL;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DNA REPAIR; ENZYME INHIBITORS; GUANIDINES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, SCID; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76049091888     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1945     Document Type: Article

References (41)

1. Giralt J, Benavente S, Arguis M. Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease. Ann Oncol 2008;19 Suppl 7: vii195-9.
2. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489-501.
3. Waldron J, Warde P, Irish J, et al. A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiother Oncol 2008;87:173-80.
4. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92.
5. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
6. Yang T, Sauve AA. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J 2006;8: E632-43.
7. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009;69:1702-5.
8. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20: 130-8.
9. Van Beijnum JR, Moerkerk PT, Gerbers AJ, et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 2002;101:118-27.
10. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
11. Hjarnaa PJ, Jonsson E, Latini S, et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999;59:5751-7.
12. Olesen UH, Christensen MK, Bjorkling F, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804.
13. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
14. 31P magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3503-13.
15. Beauparlant P, Bedard D, Bernier C, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009;20:346-54.
16. Cheung ST, Huang DP, Hui AB, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
17. Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 2002;62:171-8.
18. Ito E, Yip KW, Katz D, et al. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol 2009;76:969-83.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
20. Yip KW, Mao X, Au PY, et al. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res 2006;12:5557-69.
21. Choudhury A, Zhao H, Jalali F, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009;8:203-13.
22. 18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
24. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
25. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
26. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008;49 Suppl 2:43-63S.
27. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993;20: 308-18.
28. 18F-FDG uptake over time. J Nucl Med 2008;49:1570; author reply 1571.
29. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging 2005;32:98-101.
30. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-70.
31. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70.
32. Martinsson P, de la Torre M, Binderup L, Nygren P, Larsson R. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol 2001;417:181-7.
33. Lovborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002; 63:1491-8.
34. Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7.
35. Martinsson P, Ekelund S, Nygren P, Larsson R. The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro - from cytotoxic synergy to complete inhibition of apoptosis. Br J Pharmacol 2002;137:568-73.
36. Lombard DB, Schwer B, Alt FW, Mostoslavsky R. SIRT6 in DNA repair, metabolism and ageing. J Intern Med 2008;263:128-41.
37. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26:45-51.
38. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35: 2294-303.
39. 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 2007;69: 1222-30.
40. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-65.
41. Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007;357:150-6.